Cancer Research

Our department conducts national and internationally recognised cancer research. Our preclinical and clinical cancer research has led to changes in clinical practice and improved patient treatments.

We have a proven track record in practice-changing clinical trials in pancreatic cancer. These have set the standards for the diagnosis (PET PANC study) and adjuvant therapy (ESPAC 4 trial) for patients with pancreatic cancer. Both are part of the NICE Guidelines for the Diagnosis and Management of pancreatic cancer and ESPAC 4 is part of the American Society of Clinical Oncology Guidelines.

Examples of high impact research include:

The department is also home to the Liverpool Cancer Research Institute, led by Professor Andrew Pettitt, which aims to consolidate the existing strengths in biomedical and translational cancer research in Liverpool, grow its capability and accelerate the translation of research into improved patient outcomes.

Back to: Institute of Systems, Molecular and Integrative Biology